LivaNova Receives CE Mark for VNS Therapy SenTiva Generator and Next-Generation Programming System for Treatment of Epilepsy
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received CE Mark for its Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System comprised of the SenTiva® generator and next-generation Programming System for the treatment of patients with drug-resistant epilepsy (“DRE”). The Company received FDA approval for the full VNS Therapy System in October 2017.
The SenTiva generator offers the smallest and lightest responsive therapy with a number of new advanced features for the treatment of DRE. SenTiva is the only device of its size to include the AutoStim Mode, also known as Seizure Response Mode, which is designed to detect seizures and automatically deliver an extra dose of therapy. The generator is also designed to collect and log events including a patient’s body position and heart rate fluctuations.
The next-generation Programming System includes a small tablet and wireless programming wand compatible with the SenTiva generator and all LivaNova legacy VNS Therapy generators. When combined with SenTiva’s smart technology, the Programming System provides several advanced options and makes delivering treatment easier and more efficient through personalized patient-centric features.
“CE Mark combined with recent FDA approval for the SenTiva generator and Programming System advances VNS Therapy treatment for patients with drug-resistant epilepsy across the globe,” said Edward Andrle, LivaNova’s General Manager of its Neuromodulation business franchise. “Not only is the new VNS Therapy System simpler to use, making drug-resistant epilepsy treatment easier, the SenTiva generator and Programming System work together to allow physicians to confidently deliver proven results through customizable, smart technology. After a successful launch in the U.S., we look forward to seeing European patients benefit from our latest technology advancements.”
The new System’s features include:
- Guided Programming – Advanced technology allows physicians to quickly and confidently deliver a proven treatment with one touch.
- Scheduled Programming – Physicians can safely program multiple therapeutic steps in one office visit; the generator will then gradually and automatically increase therapy without the need for the patient to return to the physician. Scheduled programming can be very helpful, since many patients with epilepsy are not able to drive. This feature may also allow the patient to achieve a target dosage sooner.
- Day-Night Programming – Physicians have unrivalled flexibility to customize therapy for when their patients need it at specific times, day or night.
The new features will help improve patients’ overall quality of life, make VNS Therapy easier to use and bring value to the healthcare system. Treatment with VNS Therapy can result in fewer seizures, shorter seizures and faster recovery; to date, it has been used by more than 100,000 patients globally.1
“SenTiva provides exciting advances in neuromodulation therapy for drug-resistant epilepsy. The smaller size and new programming features expand the range of patients we can treat,” said Dr. David McCormick, Clinical Lead for Paediatric Neurosciences at King’s College Hospital, London. “To that end, we are pleased to announce that the first SenTiva implant in a pediatric patient in Europe took place at King’s College Hospital in London.”
1. Data on file, LivaNova PLC, Houston, TX.
About VNS Therapy for Epilepsy
VNS Therapy is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. For more information, visit www.VNSTherapy.co.uk
INTENDED USE/INDICATIONS – EU
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications.
Individual results may vary. Common side effects include hoarseness or changes in voice tone, prickling feeling in the skin, shortness of breath, sore throat and coughing. Visit http://en.eu.livanova.cyberonics.com/safety-information to view safety and full prescribing information.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 4,500 employees, inclusive of approximately 900 employed by our CRM business franchise. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.livanova.com .
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova’s control.
All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.
LivaNova PLC Investor Relations and Media
Karen King, +1 (281) 228-7262
Vice President, Investor Relations & Corporate Communications
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications – Products and Therapies
Melissa Rieger, +1 (412) 251-2172
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
NEC Iris Recognition Technology Ranks First in NIST Accuracy Testing27.4.2018 05:00 | Tiedote
NEC Corporation (NEC) (TOKYO: 6701) today announced that its iris recognition technology achieved the highest matching accuracy evaluation in the recent Iris Exchange (IREX,*1) IX evaluations of automated iris recognition algorithms performed by the U.S. National Institute of Standards and Technology (NIST). Iris recognition technology is a biometrics identifier that uses patterns from the iris, the donut-like tissue that surrounds the pupil. In recent years, this technology has been adopted by systems that require large-scale matching, mainly for organizations and companies, since it is possible to quickly provide highly accurate authentication with devices that do not require physical contact. From the standpoint of privacy protection and security enhancement, government agencies in particular are in growing need of reliable personal authentication for purposes that include citizen ID, immigration control and criminal investigations. NEC received the top accuracy ranking in the IREX
Gemalto First Quarter 2018 Revenue27.4.2018 01:00 | Tiedote
Regulatory News: Gemalto (Euronext NL0000400653 - GTO), the world leader in digital security today announces its revenue for the first quarter of 2018. Revenue (€ in millions) First quarter 2018 First quarter 2017 Change at constant exchange rates Change at historical exchange rates Identity, IoT & Cybersecurity 293 256 +24% +15% Smartcards & Issuance 357 396 (2%) (10%) Total 650 651 +8% = Philippe Vallée, Chief Executive Officer, commented: “Gemalto grew well this quarter driven by a solid increase in the Identity, IoT & Cybersecurity segment that more than offset the anticipated revenue decrease in the Smartcards & Issuance segment. During the quarter, commercial synergies with the newly acquired Identity Management business began to kick in and resulted in milestone wins in Governments. Gemalto also announced the launch of two ground-breaking laser-personalized innovations designed to significantly increase the security of passports and IDs. The Cybersecurity business grew well in E
Elliott Advisors (UK) Limited Statement on Telecom Italia26.4.2018 22:49 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”) today sent a new letter and a presentation to Telecom Italia (“TIM” or the “Company”) shareholders calling upon shareholders to uphold best practice governance principles at TIM’s upcoming shareholder meeting on May 4th. Inadequate governance and poor stewardship have imposed a heavy cost on TIM’s stakeholders for too long. Vivendi’s repeated missteps and self-serving behaviour have eroded the value of TIM’s shares and destroyed shareholder trust. The question being put to TIM shareholders on May 4th is: can you entrust your investment to Vivendi as long-term stewards of your capital and this company moving forward? Shareholders should take the opportunity to correct a governance structure rife with conflict and demand high quality and independent stewardship at the Board level. Shareholders have the opportunity to remove an otherwise permanent, persisting and pervasive impairment of value. This pivotal vote offers a textbook opportunity to put
Javier Gómez Noya Chooses ROKA Eyewear26.4.2018 21:15 | Tiedote
ROKA, the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya, expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/ Javier Gómez Noya Chooses ROKA Eyewear (Photo: Business Wire) “I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of
Egyptian Singer Becomes First Woman to Perform Before a Mixed Crowd in Saudi Arabia26.4.2018 20:55 | Tiedote
History was made in Saudi Arabia on Wednesday as a female singer performed before a mixed audience for the first time in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006471/en/ Egypt’s National Arab Music Ensemble of the Egyptian Opera House debuted in Saudi Arabia with the singer Nihad Fathy performing before a 2,500-strong audience in Riyadh. This is the first time a woman singer performed on stage in the Kingdom before a mixed crowd. (Photo courtesy of GCA Saudi Arabia.) Egypt’s National Arab Music Ensemble (AME) of the Egyptian Opera House debuted in the Kingdom with the singer Nihad Fathy performing before a 2,500-strong audience at King Fahad Cultural Center in Riyadh. The crowd broke into a rapturous applause as she took to the stage. The Egyptian Opera House ensemble, which was led by famous conductor Moustafa Helmy, comprised 45 male and female musicians and singers, including the star singers A
Pharnext Appoints Amit Kohli as Chief Operating Officer26.4.2018 19:00 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Amit Kohli, a senior healthcare industry executive, as Chief Operating Officer (COO). Mr. Kohli is responsible for leading Pharnext’s corporate strategy and operations. “Amit is a seasoned leader with over 20 years’ experience in the healthcare industry, and we are thrilled he is joining Pharnext,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are deeply impressed with Amit’s results-oriented track record, and his ability to drive business strategy and operations across the pharma, medtech and clinical diagnostics sectors. We believe Pharnext will greatly benefit from his extensive cross-functional leadership experience especially as our first-in-class orphan drug, PXT3003, for the
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme